Outcomes of SARS-CoV-2 infection among children and young people with pre-existing rheumatic and musculoskeletal diseases
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ..
OBJECTIVES: Some adults with rheumatic and musculoskeletal diseases (RMDs) are at increased risk of COVID-19-related death. Excluding post-COVID-19 multisystem inflammatory syndrome of children, children and young people (CYP) are overall less prone to severe COVID-19 and most experience a mild or asymptomatic course. However, it is unknown if CYP with RMDs are more likely to have more severe COVID-19. This analysis aims to describe outcomes among CYP with underlying RMDs with COVID-19.
METHODS: Using the European Alliance of Associations for Rheumatology COVID-19 Registry, the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry, and the CARRA-sponsored COVID-19 Global Paediatric Rheumatology Database, we obtained data on CYP with RMDs who reported SARS-CoV-2 infection (presumptive or confirmed). Patient characteristics and illness severity were described, and factors associated with COVID-19 hospitalisation were investigated.
RESULTS: 607 CYP with RMDs <19 years old from 25 different countries with SARS-CoV-2 infection were included, the majority with juvenile idiopathic arthritis (JIA; n=378; 62%). Forty-three (7%) patients were hospitalised; three of these patients died. Compared with JIA, diagnosis of systemic lupus erythematosus, mixed connective tissue disease, vasculitis, or other RMD (OR 4.3; 95% CI 1.7 to 11) or autoinflammatory syndrome (OR 3.0; 95% CI 1.1 to 8.6) was associated with hospitalisation, as was obesity (OR 4.0; 95% CI 1.3 to 12).
CONCLUSIONS: This is the most significant investigation to date of COVID-19 in CYP with RMDs. It is important to note that the majority of CYP were not hospitalised, although those with severe systemic RMDs and obesity were more likely to be hospitalised.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:81 |
|---|---|
| Enthalten in: |
Annals of the rheumatic diseases - 81(2022), 7 vom: 25. Juli, Seite 998-1005 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kearsley-Fleet, Lianne [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Arthritis, Juvenile |
|---|
| Anmerkungen: |
Date Completed 08.07.2022 Date Revised 22.07.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/annrheumdis-2022-222241 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338682643 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338682643 | ||
| 003 | DE-627 | ||
| 005 | 20231226001222.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/annrheumdis-2022-222241 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1128.xml |
| 035 | |a (DE-627)NLM338682643 | ||
| 035 | |a (NLM)35338032 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kearsley-Fleet, Lianne |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Outcomes of SARS-CoV-2 infection among children and young people with pre-existing rheumatic and musculoskeletal diseases |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.07.2022 | ||
| 500 | |a Date Revised 22.07.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a OBJECTIVES: Some adults with rheumatic and musculoskeletal diseases (RMDs) are at increased risk of COVID-19-related death. Excluding post-COVID-19 multisystem inflammatory syndrome of children, children and young people (CYP) are overall less prone to severe COVID-19 and most experience a mild or asymptomatic course. However, it is unknown if CYP with RMDs are more likely to have more severe COVID-19. This analysis aims to describe outcomes among CYP with underlying RMDs with COVID-19 | ||
| 520 | |a METHODS: Using the European Alliance of Associations for Rheumatology COVID-19 Registry, the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry, and the CARRA-sponsored COVID-19 Global Paediatric Rheumatology Database, we obtained data on CYP with RMDs who reported SARS-CoV-2 infection (presumptive or confirmed). Patient characteristics and illness severity were described, and factors associated with COVID-19 hospitalisation were investigated | ||
| 520 | |a RESULTS: 607 CYP with RMDs <19 years old from 25 different countries with SARS-CoV-2 infection were included, the majority with juvenile idiopathic arthritis (JIA; n=378; 62%). Forty-three (7%) patients were hospitalised; three of these patients died. Compared with JIA, diagnosis of systemic lupus erythematosus, mixed connective tissue disease, vasculitis, or other RMD (OR 4.3; 95% CI 1.7 to 11) or autoinflammatory syndrome (OR 3.0; 95% CI 1.1 to 8.6) was associated with hospitalisation, as was obesity (OR 4.0; 95% CI 1.3 to 12) | ||
| 520 | |a CONCLUSIONS: This is the most significant investigation to date of COVID-19 in CYP with RMDs. It is important to note that the majority of CYP were not hospitalised, although those with severe systemic RMDs and obesity were more likely to be hospitalised | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Arthritis, Juvenile | |
| 650 | 4 | |a Covid-19 | |
| 650 | 4 | |a Infections | |
| 700 | 1 | |a Chang, Min-Lee |e verfasserin |4 aut | |
| 700 | 1 | |a Lawson-Tovey, Saskia |e verfasserin |4 aut | |
| 700 | 1 | |a Costello, Ruth |e verfasserin |4 aut | |
| 700 | 1 | |a Fingerhutová, Šárka |e verfasserin |4 aut | |
| 700 | 1 | |a Švestková, Natálie |e verfasserin |4 aut | |
| 700 | 1 | |a Belot, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Aeschlimann, Florence A |e verfasserin |4 aut | |
| 700 | 1 | |a Melki, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Koné-Paut, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Eulert, Sascha |e verfasserin |4 aut | |
| 700 | 1 | |a Kallinich, Tilmann |e verfasserin |4 aut | |
| 700 | 1 | |a Berkun, Yackov |e verfasserin |4 aut | |
| 700 | 1 | |a Uziel, Yosef |e verfasserin |4 aut | |
| 700 | 1 | |a Raffeiner, Bernd |e verfasserin |4 aut | |
| 700 | 1 | |a Oliveira Ramos, Filipa |e verfasserin |4 aut | |
| 700 | 1 | |a Clemente, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Dackhammar, Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Wulffraat, Nico M |e verfasserin |4 aut | |
| 700 | 1 | |a Waite, Helen |e verfasserin |4 aut | |
| 700 | 1 | |a Strangfeld, Anja |e verfasserin |4 aut | |
| 700 | 1 | |a Mateus, Elsa F |e verfasserin |4 aut | |
| 700 | 1 | |a Machado, Pedro M |e verfasserin |4 aut | |
| 700 | 0 | |a CARRA Registry Investigators |e verfasserin |4 aut | |
| 700 | 0 | |a COVID-19 Global Pediatric Rheumatology Database Investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Natter, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Hyrich, Kimme L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of the rheumatic diseases |d 1939 |g 81(2022), 7 vom: 25. Juli, Seite 998-1005 |w (DE-627)NLM000174114 |x 1468-2060 |7 nnns |
| 773 | 1 | 8 | |g volume:81 |g year:2022 |g number:7 |g day:25 |g month:07 |g pages:998-1005 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/annrheumdis-2022-222241 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 81 |j 2022 |e 7 |b 25 |c 07 |h 998-1005 | ||